CoChat
Sign Up
Cited by 87Tuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisHIV, TB, and STIs Epidemiology

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis

Reid, Michael, Agbassi, Yvan Jean Patrick, Arinaminpathy, Nimalan, Bercasio, Alyssa, Bhargava, Anurag, Bhargava, Madhavi, Bloom, Amy, Cattamanchi, Adithya, Chaisson, Richard, Chin, Daniel, Churchyard, Gavin, Cox, Helen, Denkinger, Claudia M, Ditiu, Lucica, Dowdy, David, Dybul, Mark, Fauci, Anthony, Fedaku, Endalkachew, Gidado, Mustapha, Harrington, Mark, Hauser, Janika, Heitkamp, Petra, Herbert, Nick, Herna Sari, Ani, Hopewell, Philip, Kendall, Emily, Khan, Aamir, Kim, Andrew, Koek, Irene, Kondratyuk, Sergiy, Krishnan, Nalini, Ku, Chu-Chang, Lessem, Erica, McConnell, Erin V, Nahid, Payam, Oliver, Matt, Pai, Madhukar, Raviglione, Mario, Ryckman, Theresa, Schäferhoff, Marco, Silva, Sachin, Small, Peter, Stallworthy, Guy, Temesgen, Zelalem, van Weezenbeek, Kitty, Vassall, Anna, Velásquez, Gustavo E, Venkatesan, Nandita, Yamey, Gavin, Zimmerman, Armand, Jamison, Dean, Swaminathan, Soumya, Goosby, Eric·2023·The Lancet
DOI 10.1016/s0140-6736(23)01379-x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)01379-x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A new set of tuberculosis control technologies provides grounds for optimism in reaching a tuberculosis-free world within a generation.

    “Last year, the Lancet Commission on Tuberculosis published its report “Scientific advances and the end of tuberculosis,” which argued that a new set of tuberculosis control technologies provided grounds for optimism in reaching a tuberculosis-free world within a generation.52”

    From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [52]

  • Using new diagnostics along the case finding cascade could reap large benefits.

    “Using new diagnostics along the case finding “cascade”—for those with subclinical tuberculosis, those with symptoms who have not sought care, and those who have sought care but are undiagnosed—could reap large benefits.52”

    From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [52]

  • The WHO and the US Centers for Disease Control and Prevention recently approved the 4-month isoniazid-rifapentine-moxifloxacin-pyrazinamide (4HPMZ) regimen for eligible people with drug-susceptible tuberculosis.

    “The WHO and the US Centers for Disease Control and Prevention recently approved the 4-month isoniazid–rifapentine–moxifloxacin–pyrazinamide (4HPMZ) regimen for eligible people with drug-susceptible tuberculosis, which “speaks to the momentum of the development of new treatments for drug-susceptible tuberculosis.”52”

    From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [52]

  • For a tuberculosis-free world within a generation, new tuberculosis control tools would need to be adopted wholesale, implemented at scale, and accompanied by sustained investment in development of new tools and in tuberculosis programmes.

    “Such tools, it argued, would need to be adopted wholesale, implemented at scale, and accompanied by sustained investment in development of new tools and in tuberculosis programmes for this vision to be achieved.”

    From Global health 2050: the path to halving premature death by mid-century (2024) · cites this paper as [52]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 144

  1. Reid, 2019, Building a tuberculosis-free world: The Lancet Commission on tuberculosis, Lancet, 393, 1331, 10.1016/S0140-6736(19)30024-8 · DOI
  2. Ndjeka, 2022, Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study, Lancet Infect Dis, 22, 1042, 10.1016/S1473-3099(21)00811-2 · DOI
  3. Ryckman, 2023, Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach, Lancet Infect Dis, 23, e59, 10.1016/S1473-3099(22)00500-X · DOI
  4. Zimmer, 2021, Facility-based directly observed therapy (DOT) for tuberculosis during COVID-19: a community perspective, J Clin Tuberc Other Mycobact Dis, 24
  5. Zimmer, 2022, Tuberculosis in times of COVID-19, J Epidemiol Community Health, 76, 310, 10.1136/jech-2021-217529 · DOI
  6. Grange, 1999, Paradox of the global emergency of tuberculosis, Lancet, 353, 996, 10.1016/S0140-6736(99)01196-4 · DOI
  7. Raviglione, 2006, WHO's new Stop TB Strategy, Lancet, 367, 952, 10.1016/S0140-6736(06)68392-X · DOI
  8. Das, 2010, Tuberculosis—time to accelerate progress, Lancet, 375, 1755, 10.1016/S0140-6736(10)60600-9 · DOI
  9. Lönnroth, 2010, Tuberculosis control and elimination 2010–50: cure, care, and social development, Lancet, 375, 1814, 10.1016/S0140-6736(10)60483-7 · DOI
  10. Uplekar, 2015, WHO's End TB Strategy: from stopping to ending the global TB epidemic, Indian J Tuberc, 62, 196, 10.1016/j.ijtb.2015.11.001 · DOI
  11. Floyd, 2018, The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era, Lancet Respir Med, 6, 299, 10.1016/S2213-2600(18)30057-2 · DOI
  12. Raviglione, 2018, Tuberculosis makes it onto the international political agenda for health…finally, Lancet Glob Health, 6, e20, 10.1016/S2214-109X(17)30449-7 · DOI
  13. Kim, 2019, Health systems performance in managing tuberculosis: analysis of tuberculosis care cascades among high-burden and non-high-burden countries, J Glob Health, 9, 10.7189/jogh.09.010423 · DOI
  14. Horne, 2019, Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults, Cochrane Database Syst Rev, 6
  15. Ryckman, 2022, Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach, Lancet Infect Dis
  16. Dheda, 2022, The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions, Lancet Respir Med, 10, 603, 10.1016/S2213-2600(22)00092-3 · DOI
  17. McQuaid, 2021, The impact of COVID-19 on TB: a review of the data, Int J Tuberc Lung Dis, 25, 436, 10.5588/ijtld.21.0148 · DOI
  18. Malik, 2020, Tuberculosis control and care in the era of COVID-19, Health Policy Plan, 35, 1130, 10.1093/heapol/czaa109 · DOI
  19. Boniol, 2022, Urgent need to invest in health and care workers, Lancet, 399, 2079, 10.1016/S0140-6736(22)00576-1 · DOI
  20. Nikolayevskyy, 2021, Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe, Eur Respir J, 57, 10.1183/13993003.03890-2020 · DOI
  21. Nachega, 2021, From easing lockdowns to scaling up community-based coronavirus disease 2019 screening, testing, and contact tracing in Africa—shared approaches, innovations, and challenges to minimize morbidity and mortality, Clin Infect Dis, 72, 327, 10.1093/cid/ciaa695 · DOI
  22. Fei, 2020, The impact of the COVID-19 epidemic on tuberculosis control in China, Lancet Reg Health West Pac, 3
  23. Glaziou, 2021, Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020, medRxiv
  24. Cilloni, 2020, The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis, EClinicalMedicine, 28, 10.1016/j.eclinm.2020.100603 · DOI
  25. McQuaid, 2020, The potential impact of COVID-19-related disruption on tuberculosis burden, Eur Respir J, 56, 10.1183/13993003.01718-2020 · DOI
  26. Saulnier, 2021, A health systems resilience research agenda: moving from concept to practice, BMJ Glob Health, 6, 10.1136/bmjgh-2021-006779 · DOI
  27. Watkins, 2018, Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health, Lancet, 392, 1434, 10.1016/S0140-6736(18)32389-4 · DOI · Paper page
  28. Hannay, 2023, Breaking the cycle of neglect: building on momentum from COVID-19 to drive access to diagnostic testing, EClinicalMedicine, 57, 10.1016/j.eclinm.2023.101867 · DOI
  29. Vogensen, 2022, The case for expanding worldwide access to point of care molecular drug susceptibility testing for isoniazid, Clin Microbiol Infect, 28, 1047, 10.1016/j.cmi.2022.03.033 · DOI
  30. Chang, 2023, Circulating cell-free RNA in blood as a host response biomarker for the detection of tuberculosis, medRxiv
  31. Gaur, 2020, Diagnostic performance of non-invasive, stool-based molecular assays in patients with paucibacillary tuberculosis, Sci Rep, 10, 10.1038/s41598-020-63901-z · DOI
  32. Luabeya, 2019, Noninvasive detection of tuberculosis by oral swab analysis, J Clin Microbiol, 57, e01847, 10.1128/JCM.01847-18 · DOI
  33. Codsi, 2022, Preferences of health care workers using tongue swabs for tuberculosis diagnosis during COVID-19, medRxiv
  34. Kang, 2022, Gene-based diagnosis of tuberculosis from oral swabs with a new generation pathogen enrichment technique, Microbiol Spectr, 10, 10.1128/spectrum.00207-22 · DOI
  35. Andama, 2022, Accuracy of tongue swab testing using Xpert MTB-RIF Ultra for tuberculosis diagnosis, J Clin Microbiol, 60, 10.1128/jcm.00421-22 · DOI
  36. Shapiro, 2022, Complementary nonsputum diagnostic testing for tuberculosis in people with HIV using oral swab PCR and urine lipoarabinomannan detection, J Clin Microbiol, 60, 10.1128/jcm.00431-22 · DOI
  37. Manguro, 2022, Are Kenyans likely to use COVID-19 self-testing kits? Results from a cross-sectional survey, Int J Public Health, 67, 10.3389/ijph.2022.1604918 · DOI
  38. Nguyen, 2022, A mixed methods study evaluating acceptability of a daily COVID-19 testing regimen with a mobile-app connected, at-home, rapid antigen test: implications for current and future pandemics, PLoS One, 17, 10.1371/journal.pone.0267766 · DOI
  39. Bonnet, 2023, High performance of systematic combined urine LAM test and sputum Xpert MTB/RIF® for tuberculosis screening in severely immunosuppressed ambulatory adults with HIV, Clin Infect Dis, 10.1093/cid/ciad125 · DOI
  40. Székely, 2022, Multicentre accuracy trial of FUJIFILM SILVAMP TB LAM test in people with HIV reveals lot variability, medRxiv
  41. Nguyen, 2023, Disease transmission by subclinical tuberculosis patients, Clin Infect Dis, 76, 2000, 10.1093/cid/ciad027 · DOI · Paper page
  42. Ryckman, 2022, Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications, Proc Natl Acad Sci USA, 119, 10.1073/pnas.2211045119 · DOI
  43. Botha, 2018, Detection of tuberculosis by automatic cough sound analysis, Physiol Meas, 39, 10.1088/1361-6579/aab6d0 · DOI
  44. Yellapu, 2022, Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB, medRxiv
  45. Pathri, 2022, Acoustic epidemiology of pulmonary tuberculosis (TB) & Covid19 leveraging AI/ML, medRxiv
  46. Huddart, 2023, Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring, Int J Tuberc Lung Dis, 27, 221, 10.5588/ijtld.22.0511 · DOI
  47. Albert, 2020, Designing an optimized diagnostic network to improve access to TB diagnosis and treatment in Lesotho, PLoS One, 15, 10.1371/journal.pone.0233620 · DOI
  48. Girdwood, 2023, The integration of tuberculosis and HIV testing on GeneXpert can substantially improve access and same-day diagnosis and benefit tuberculosis programmes: a diagnostic network optimization analysis in Zambia, PLOS Glob Public Health, 3, 10.1371/journal.pgph.0001179 · DOI
  49. Fleming, 2021, The Lancet Commission on diagnostics: transforming access to diagnostics, Lancet, 398, 1997, 10.1016/S0140-6736(21)00673-5 · DOI
  50. Chauhan, 2023, The prevalence of tuberculosis infection in India: a systematic review and meta-analysis, Indian J Med Res, 157, 135, 10.4103/ijmr.ijmr_382_23 · DOI
  51. Zwerling, 2014, Modeling of novel diagnostic strategies for active tuberculosis—a systematic review: current practices and recommendations, PLoS One, 9, 10.1371/journal.pone.0110558 · DOI
  52. Dowdy, 2012, Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics, Proc Natl Acad Sci USA, 109, 9557, 10.1073/pnas.1203517109 · DOI
  53. Pai, 2023, Transforming tuberculosis diagnosis, Nat Microbiol, 8, 756, 10.1038/s41564-023-01365-3 · DOI · Paper page
  54. MacLean, 2023, Integrating tuberculosis and COVID-19 molecular testing in Lima, Peru: a cross-sectional, diagnostic accuracy study, Lancet Microbe, 4, e452, 10.1016/S2666-5247(23)00042-3 · DOI
  55. Dye, 2013, Prospects for tuberculosis elimination, Annu Rev Public Health, 34, 271, 10.1146/annurev-publhealth-031912-114431 · DOI
  56. Abu-Raddad, 2009, Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics, Proc Natl Acad Sci USA, 106, 13980, 10.1073/pnas.0901720106 · DOI
  57. Dorman, 2021, Four-month rifapentine regimens with or without moxifloxacin for tuberculosis, N Engl J Med, 384, 1705, 10.1056/NEJMoa2033400 · DOI
  58. Nyang'wa, 2022, A 24-week, all-oral regimen for rifampin-resistant tuberculosis, N Engl J Med, 387, 2331, 10.1056/NEJMoa2117166 · DOI
  59. McKenna, 2023, The 1/4/6×24 campaign to cure tuberculosis quickly, Nat Med, 29, 16, 10.1038/s41591-022-02136-z · DOI
  60. Gillard, 2016, Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study, Tuberculosis (Edinb), 100, 118, 10.1016/j.tube.2016.07.005 · DOI
  61. Carr, 2022, Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis—United States, 2022, MMWR Morb Mortal Wkly Rep, 71, 285, 10.15585/mmwr.mm7108a1 · DOI
  62. Fox, 1999, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, S231
  63. Paton, 2023, Treatment strategy for rifampin-susceptible tuberculosis, N Eng J Med, 388, 873, 10.1056/NEJMoa2212537 · DOI
  64. Goodall, 2022, Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial, Lancet, 400, P1858, 10.1016/S0140-6736(22)02078-5 · DOI
  65. Conradie, 2020, Treatment of highly drug-resistant pulmonary tuberculosis, N Engl J Med, 382, 893, 10.1056/NEJMoa1901814 · DOI
  66. Conradie, 2022, Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis, N Engl J Med, 387, 810, 10.1056/NEJMoa2119430 · DOI
  67. Gomez, 2021, Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines, BMJ Open, 11, 10.1136/bmjopen-2021-051521 · DOI
  68. Sweeney, 2022, Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis, PLoS Glob Public Health, 2, 10.1371/journal.pgph.0001337 · DOI
  69. Rosu, 2023, Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial, Lancet Glob Health, 11, e265, 10.1016/S2214-109X(22)00498-3 · DOI
  70. Ochalek, 2018, Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data, BMJ Glob Health, 3, 10.1136/bmjgh-2018-000964 · DOI
  71. Capeding, 2022, Cost of TB prevention and treatment in the Philippines in 2017, Int J Tuberc Lung Dis, 26, 392, 10.5588/ijtld.21.0622 · DOI
  72. Chatterjee, 2021, Costs of TB services in India (no 1), Int J Tuberc Lung Dis, 25, 1013, 10.5588/ijtld.21.0105 · DOI
  73. Vassall, 2017, Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation, Lancet Glob Health, 5, e710, 10.1016/S2214-109X(17)30205-X · DOI
  74. Florentino, 2022, Expansion of social protection is necessary towards zero catastrophic costs due to TB: the first national TB patient cost survey in the Philippines, PLoS One, 17, 10.1371/journal.pone.0264689 · DOI
  75. Chandra, 2020, Direct and indirect patient costs of tuberculosis care in India, Trop Med Int Health, 25, 803, 10.1111/tmi.13402 · DOI
  76. Rupani, 2020, Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India, Infect Dis Poverty, 9, 144, 10.1186/s40249-020-00760-w · DOI
  77. Foster, 2015, The economic burden of TB diagnosis and treatment in South Africa, Soc Sci Med, 130, 42, 10.1016/j.socscimed.2015.01.046 · DOI
  78. Ammerman, 2022, Potential impact of long-acting products on the control of tuberculosis: preclinical advancements and translational tools in preventive treatment, Clin Infect Dis, 75, S510, 10.1093/cid/ciac672 · DOI
  79. Swindells, 2018, Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges, Int J Tuberc Lung Dis, 22, 125, 10.5588/ijtld.17.0486 · DOI
  80. Swindells, 2020, Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression, N Engl J Med, 382, 1112, 10.1056/NEJMoa1904398 · DOI
  81. Overton, 2021, Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study, Lancet, 396, 1994, 10.1016/S0140-6736(20)32666-0 · DOI
  82. Martinson, 2011, New regimens to prevent tuberculosis in adults with HIV infection, N Engl J Med, 365, 11, 10.1056/NEJMoa1005136 · DOI
  83. Sterling, 2011, Three months of rifapentine and isoniazid for latent tuberculosis infection, N Engl J Med, 365, 2155, 10.1056/NEJMoa1104875 · DOI
  84. Swindells, 2019, One Month of rifapentine plus isoniazid to prevent HIV-related tuberculosis, N Engl J Med, 380, 1001, 10.1056/NEJMoa1806808 · DOI
  85. Ryckman, 2023, Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis, Lancet Glob Health, 11, e1205, 10.1016/S2214-109X(23)00251-6 · DOI
  86. Johnson, 2018, Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings, Clin Infect Dis, 67, 1072, 10.1093/cid/ciy230 · DOI
  87. Zhu, 2022, Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania, Lancet Glob Health, 10, e1646, 10.1016/S2214-109X(22)00372-2 · DOI
  88. Havumaki, 2021, Protective impacts of household-based tuberculosis contact tracing are robust across endemic incidence levels and community contact patterns, PLoS Comput Biol, 17, 10.1371/journal.pcbi.1008713 · DOI
  89. Dockrell, 2022, Tuberculosis vaccines in the era of Covid-19—what is taking us so long?, EBioMedicine, 79, 10.1016/j.ebiom.2022.103993 · DOI
  90. Wilkie, 2015, TB vaccine development: where are we and why is it so difficult?, Thorax, 70, 299, 10.1136/thoraxjnl-2014-205202 · DOI
  91. Pai, 2022, Covid-19's devastating effect on tuberculosis care—a path to recovery, N Engl J Med, 386, 1490, 10.1056/NEJMp2118145 · DOI
  92. Van Der Meeren, 2018, Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis, N Engl J Med, 379, 1621, 10.1056/NEJMoa1803484 · DOI
  93. Harris, 2020, Potential impact of tuberculosis vaccines in China, South Africa, and India, Sci Transl Med, 12, 10.1126/scitranslmed.aax4607 · DOI
  94. Weerasuriya, 2021, The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China, BMC Med, 19, 60, 10.1186/s12916-021-01932-7 · DOI
  95. Fu, 2021, Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine, Nat Commun, 12, 424, 10.1038/s41467-020-20731-x · DOI
  96. Chatterjee, 2018, Variation in cost and performance of routine immunisation service delivery in India, BMJ Glob Health, 3, 10.1136/bmjgh-2018-000794 · DOI
  97. Portnoy, 2023, The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modeling study, PLoS Med, 20
  98. Scriba, 2020, Key recent advances in TB vaccine development and understanding of protective immune responses against mycobacterium tuberculosis, Semin Immunol, 50, 10.1016/j.smim.2020.101431 · DOI
  99. Golob, 2021, SARS-CoV-2 vaccines: a triumph of science and collaboration, JCI Insight, 6, 10.1172/jci.insight.149187 · DOI
  100. Yamey, 2021, Developing vaccines for neglected and emerging infectious diseases, BMJ, 372, n373, 10.1136/bmj.n373 · DOI
  101. Wouters, 2021, Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment, Lancet, 397, 1023, 10.1016/S0140-6736(21)00306-8 · DOI
  102. Kerkhoff, 2022, Addressing health disparities through implementation science-a need to integrate an equity lens from the outset, Implement Sci, 17, 13, 10.1186/s13012-022-01189-5 · DOI
  103. Vesga, 2019, Assessing tuberculosis control priorities in high-burden settings: a modelling approach, Lancet Glob Health, 7, e585, 10.1016/S2214-109X(19)30037-3 · DOI
  104. Ehrenkranz, 2019, Differentiated service delivery: navigating the path to scale, Curr Opin HIV AIDS, 14, 60, 10.1097/COH.0000000000000509 · DOI
  105. Odone, 2018, People- and patient-centred care for tuberculosis: models of care for tuberculosis, Int J Tuberc Lung Dis, 22, 133, 10.5588/ijtld.17.0608 · DOI
  106. Farmer, 1999, Pathologies of power: rethinking health and human rights, Am J Public Health, 89, 1486, 10.2105/AJPH.89.10.1486 · DOI
  107. Kerkhoff, 2023, A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment, Curr Opin HIV AIDS, 18, 32, 10.1097/COH.0000000000000776 · DOI
  108. Kerkhoff, 2021, Pathways to care and preferences for improving tuberculosis services among tuberculosis patients in Zambia: a discrete choice experiment, PLoS One, 16, 10.1371/journal.pone.0252095 · DOI
  109. Citro, 2021, Building the evidence for a rights-based, people-centered, gender-transformative tuberculosis response: an analysis of the Stop TB partnership community, rights, and gender tuberculosis assessment, Health Hum Rights, 23, 253
  110. Anderson, 2020, Using socioeconomics to counter health disparities arising from the Covid-19 pandemic, BMJ, 369
  111. Maharjan, 2021, A scoping review on climate change and tuberculosis, Int J Biometeorol, 65, 1579, 10.1007/s00484-021-02117-w · DOI
  112. Kharwadkar, 2022, The impact of climate change on the risk factors for tuberculosis: a systematic review, Environ Res, 212, 10.1016/j.envres.2022.113436 · DOI
  113. Bhargava, 2014, Undernutrition and the incidence of tuberculosis in India: national and subnational estimates of the population-attributable fraction related to undernutrition, Natl Med J India, 27, 128
  114. Bhargava, 2022, Attributable is preventable: corrected and revised estimates of population attributable fraction of TB related to undernutrition in 30 high TB burden countries, J Clin Tuberc Other Mycobact Dis, 27
  115. McQuaid, 2023, Tuberculosis and nutrition: what gets measured gets managed, Lancet Respir Med, 11, 308, 10.1016/S2213-2600(23)00009-7 · DOI
  116. Bhargava, 2021, BMJ Open, 11, 10.1136/bmjopen-2020-047210 · DOI
  117. Bhargava, 2023, Nutritional support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes in a programmatic cohort nested within the RATIONS trial in Jharkhand, India, Lancet Glob Health, 11, e1402, 10.1016/S2214-109X(23)00324-8 · DOI
  118. Bhargava, 2023, Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial, Lancet, 402, 627, 10.1016/S0140-6736(23)01231-X · DOI
  119. Pai, 2022, Covid-19's devastating effect on tuberculosis care—a path to recovery, N Engl J Med, 386, 1490, 10.1056/NEJMp2118145 · DOI
  120. Reeves, 2015, Tuberculosis control and economic recession: longitudinal study of data from 21 European countries, 1991–2012, Bull World Health Organ, 93, 369, 10.2471/BLT.14.142356 · DOI
  121. Martínez Álvarez, 2016, Is development assistance for health fungible? Findings from a mixed methods case study in Tanzania, Soc Sci Med, 159, 161, 10.1016/j.socscimed.2016.05.006 · DOI
  122. Kentikelenis, 2022, Austerity Redux: The post-pandemic wave of budget cuts and the future of global public health, Glob Policy, 13, 5, 10.1111/1758-5899.13028 · DOI
  123. Boyce, 2023, An early analysis of the World Bank's Pandemic Fund: a new fund for pandemic prevention, preparedness and response, BMJ Glob Health, 8, 10.1136/bmjgh-2022-011172 · DOI
  124. Burki, 2022, The replenishment of the Global Fund, Lancet Infect Dis, 22, 1546, 10.1016/S1473-3099(22)00675-2 · DOI
  125. Panel TI. COVID-19: make it the last pandemic. Interdependent Panel for Pandemic Preparedness and Response, 2021. · DOI
  126. Saavedra, 2023, Funding pandemic prevention, preparedness, and response through partnership models, Lancet Public Health, 8, e13, 10.1016/S2468-2667(22)00291-2 · DOI
  127. Ruhwald, 2022, Considerations for simultaneous testing of COVID-19 and tuberculosis in high-burden countries, Lancet Glob Health, 10, e465, 10.1016/S2214-109X(22)00002-X · DOI
  128. Homolka, 2020, Two pandemics, one challenge—leveraging molecular test capacity of tuberculosis laboratories for rapid covid-19 case-finding, Emerg Infect Dis, 26, 2549, 10.3201/eid2611.202602 · DOI
  129. Agus, 2023, COVID-19 and other adult vaccines can drive global disease prevention, Lancet, 401, 8, 10.1016/S0140-6736(22)02084-0 · DOI
  130. Oxlade, 2009, Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health?, Int J Tuberc Lung Dis, 13, 1238
  131. Roth, 2018, Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems, Global Health, 14, 102, 10.1186/s12992-018-0421-2 · DOI
  132. Basu, 2012, Comparative performance of private and public healthcare systems in low- and middle-income countries: a systematic review, PLoS Med, 9, 10.1371/journal.pmed.1001244 · DOI
  133. Yamey, 2017, Financing of international collective action for epidemic and pandemic preparedness, Lancet Glob Health, 5, e742, 10.1016/S2214-109X(17)30203-6 · DOI
  134. Stallworthy, 2020, Quality of tuberculosis care in the private health sector, J Clin Tuberc Other Mycobact Dis, 20
  135. Carter, 2018, The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1, Lancet Glob Health, 6, e514, 10.1016/S2214-109X(18)30195-5 · DOI
  136. Dheda, 2014, Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa, Lancet Glob Health, 2, e554, 10.1016/S2214-109X(14)70305-5 · DOI
  137. Dowdy, 2014, Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling, Int J Tuberc Lung Dis, 18, 1012, 10.5588/ijtld.13.0851 · DOI
  138. Langley, 2014, Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach, Lancet Glob Health, 2, e581, 10.1016/S2214-109X(14)70291-8 · DOI
  139. Gotham, 2020, Public investments in the clinical development of bedaquiline, PLoS One, 15, 10.1371/journal.pone.0239118 · DOI
  140. Gotham, 2021, Public investments in the development of GeneXpert molecular diagnostic technology, PLoS One, 16, 10.1371/journal.pone.0256883 · DOI
  141. Ooms, 2019, Threat of compulsory licences could increase access to essential medicines, BMJ, 365
  142. Morin, 2022, The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study, Lancet Public Health, 7, e169, 10.1016/S2468-2667(21)00202-4 · DOI
  143. Juneja, 2017, Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP), PLoS One, 12, 10.1371/journal.pone.0177770 · DOI
  144. Junod Moser, 2023, Striking fair deals for equitable access to medicines, J Intellect Prop Law Pract, 18, 323

Cited by

Sorted by citations

Metadata

Authors
Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., Churchyard, G., Cox, H., Denkinger, C. M., Ditiu, L., Dowdy, D., Dybul, M., Fauci, A., Fedaku, E., Gidado, M., Harrington, M., Hauser, J., Heitkamp, P., Herbert, N., Herna Sari, A., Hopewell, P., Kendall, E., Khan, A., Kim, A., Koek, I., Kondratyuk, S., Krishnan, N., Ku, C.-C., Lessem, E., McConnell, E. V., Nahid, P., Oliver, M., Pai, M., Raviglione, M., Ryckman, T., Schäferhoff, M., Silva, S., Small, P., Stallworthy, G., Temesgen, Z., van Weezenbeek, K., Vassall, A., Velásquez, G. E., Venkatesan, N., Yamey, G., Zimmerman, A., Jamison, D., Swaminathan, S., & Goosby, E.
Affiliations
  • University of California, San Francisco (US)
  • Yenepoya University (IN)
  • Imperial College London (GB)
  • United States Agency for International Development (US)
  • University of California, Irvine (US)
  • Johns Hopkins University (US)
  • Gates Foundation (US)
  • Aurum Institute (ZA)
  • University of Cape Town (ZA)
  • University Hospital Heidelberg (DE)
  • Georgetown University (US)
  • National Institutes of Health (US)
  • KNCV TB Plus (NL)
  • Treatment Action Group (US)
  • McGill University (CA)
  • Parliament of United Kingdom (GB)
  • Interactive Research and Development (PK)
  • Save the Children (US)
  • University of Milan (IT)
  • Harvard University (US)
  • Mayo Clinic (US)
  • London School of Hygiene & Tropical Medicine (GB)
  • University of Oxford (GB)
  • Duke University (US)
  • M S Swaminathan Research Foundation (IN)
Corresponding author
Reid, Michael
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-10
Volume
402
Issue
10411
Pages
1473-1498
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(23)01379-x
OpenAlex
W4386700370
Cited by
87
References
4
Citations by year
2026: 26 · 2025: 33 · 2024: 25 · 2023: 3
FWCI
4.13
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • World Health Organization
  • Medical Research Council (MR/R015600/1)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
Keywords
tuberculosis, tuberculosis elimination, drug-resistant tuberculosis, tuberculosis treatment outcomes, tuberculosis mortality
MeSH terms
Humans, Tuberculosis, Global Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review